公开(公告)号：US07037644B1

公开(公告)日：2006-05-02

申请号：US09320299

申请日：1999-05-26

申请人： Jeannette Whitcomb

发明人： Jeannette Whitcomb

IPC分类号： C12Q1/70

CPC分类号： C12Q1/703

摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

公开(公告)号：US09581595B2

公开(公告)日：2017-02-28

申请号：US12527863

申请日：2008-02-26

申请人： Wei Huang ,  Signe Fransen ,  Christos Petropoulos ,  Jonathan Toma ,  Jeannette Whitcomb

发明人： Wei Huang ,  Signe Fransen ,  Christos Petropoulos ,  Jonathan Toma ,  Jeannette Whitcomb

IPC分类号： G01N33/00 ,  G01N33/569

CPC分类号： C12Q1/703 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/56988 ,  G01N2333/16 ,  G01N2333/162 ,  G01N2800/52

摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.

摘要翻译： 本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。 在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性 艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。

公开(公告)号：US20060183110A1

公开(公告)日：2006-08-17

申请号：US11233461

申请日：2005-09-21

申请人： Christos Petropoulos ,  Neil Parkin ,  Jeannette Whitcomb ,  Wei Huang

发明人： Christos Petropoulos ,  Neil Parkin ,  Jeannette Whitcomb ,  Wei Huang

IPC分类号： C12Q1/70

CPC分类号： C12Q1/70 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5091 ,  G01N33/56983

摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which, lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

摘要翻译： 本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。

公开(公告)号：US20080293038A1

公开(公告)日：2008-11-27

申请号：US11915307

申请日：2006-05-25

申请人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

发明人： Neil T. Parkin ,  Colombe Chappey ,  Jeannette Whitcomb

IPC分类号： C12Q1/70

CPC分类号： C12Q1/6883 ,  C12Q2600/156

摘要： The present invention provides methods and devices for predicting whether an HIV-1 is resistant to an antiviral drug based on the HIV-1's genotype. In one aspect, the invention provides methods comprising determining whether a mutation or combination of mutations associated with NRTI resistance are present, as disclosed herein, thereby assessing the effectiveness of FTC therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV-1 resistance are provided.

摘要翻译： 本发明提供了用于预测HIV-1是否对基于HIV-1的基因型的抗病毒药具有抗性的方法和装置。 一方面，本发明提供了如本文所公开的确定是否存在与NRTI抗性相关的突变或突变的组合的方法，从而评估FTC治疗在HIV感染的受试者中的有效性。 提供了确定HIV-1抗性的计算机实施方法。

公开(公告)号：US20050059033A1

公开(公告)日：2005-03-17

申请号：US10758683

申请日：2004-01-14

申请人： Jeannette Whitcomb

发明人： Jeannette Whitcomb

IPC分类号： C12Q1/68 ,  C12Q1/70 ,  C07H21/04

CPC分类号： C12Q1/703

摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly non-nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

摘要翻译： 本发明涉及用于鉴定用于治疗人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）的有效药物方案的抗病毒药物敏感性和抗性测试，并且还涉及监测临床进展的手段和方法 HIV感染及其对抗逆转录病毒治疗的反应，特别是使用表型易感性测定或基因型测定的非核苷逆转录酶抑制剂治疗。

公开(公告)号：US06653081B2

公开(公告)日：2003-11-25

申请号：US09881033

申请日：2001-06-12

申请人： Jeannette Whitcomb

发明人： Jeannette Whitcomb

IPC分类号： C12Q168

CPC分类号： C12Q1/703

摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

摘要翻译： 本发明涉及用于鉴定用于治疗人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）的有效药物方案的抗病毒药物敏感性和抗性测试，并且还涉及监测临床进展的手段和方法 艾滋病毒感染及其对抗逆转录病毒治疗的反应，特别是使用表型易感性测定或基因型测定的核苷逆转录酶抑制剂治疗。

公开(公告)号：US20110033836A1

公开(公告)日：2011-02-10

申请号：US12635539

申请日：2009-12-10

申请人： DOUGLAS RICHMAN ,  MARY T. WRIN ,  SUSAN LITTLE ,  CHRISTOS J. PETROPOULOS ,  NEIL T. PARKIN ,  JEANNETTE WHITCOMB ,  WEI HUANG

发明人： DOUGLAS RICHMAN ,  MARY T. WRIN ,  SUSAN LITTLE ,  CHRISTOS J. PETROPOULOS ,  NEIL T. PARKIN ,  JEANNETTE WHITCOMB ,  WEI HUANG

IPC分类号： C12Q1/70

CPC分类号： G01N33/56988 ,  C07K14/005 ,  C07K14/16 ,  C07K14/162 ,  C07K16/08 ,  C07K16/10 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5044 ,  G01N33/5091 ,  G01N33/56983 ,  G01N2333/16

摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

摘要翻译： 本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。

公开(公告)号：US20050214743A1

公开(公告)日：2005-09-29

申请号：US10504921

申请日：2003-02-14

申请人： Douglas Richman ,  Mary Wrin ,  Susan Little ,  Christos Petropoulos ,  Neil Parkin ,  Jeannette Whitcomb ,  Wei Huang

发明人： Douglas Richman ,  Mary Wrin ,  Susan Little ,  Christos Petropoulos ,  Neil Parkin ,  Jeannette Whitcomb ,  Wei Huang

IPC分类号： C12N15/86 ,  C12Q1/68 ,  C12Q1/70

CPC分类号： G01N33/56988 ,  C07K14/005 ,  C07K14/16 ,  C07K14/162 ,  C07K16/08 ,  C07K16/10 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5044 ,  G01N33/5091 ,  G01N33/56983 ,  G01N2333/16

摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

摘要翻译： 本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸添加，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。

公开(公告)号：US06489098B1

公开(公告)日：2002-12-03

申请号：US09339357

申请日：1999-06-23

申请人： Christos J. Petropoulos ,  Jeannette Whitcomb

发明人： Christos J. Petropoulos ,  Jeannette Whitcomb

IPC分类号： C12Q170

CPC分类号： C12Q1/703 ,  C12Q2600/156

摘要： This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

摘要翻译： 本发明涉及用于鉴定用于治疗人类免疫缺陷病毒（HIV）感染和获得性免疫缺陷综合征（AIDS）的有效药物方案的抗病毒药物敏感性和抗性测试，并且还涉及监测临床进展的手段和方法 艾滋病毒感染及其对抗逆转录病毒治疗的反应，特别是使用表型易感性测定或基因型测定的核苷逆转录酶抑制剂治疗。

公开(公告)号：US09175355B2

公开(公告)日：2015-11-03

申请号：US12635539

申请日：2009-12-10

申请人： Douglas Richman ,  Mary T. Wrin ,  Susan Little ,  Christos J. Petropoulos ,  Neil T. Parkin ,  Jeannette Whitcomb ,  Wei Huang

发明人： Douglas Richman ,  Mary T. Wrin ,  Susan Little ,  Christos J. Petropoulos ,  Neil T. Parkin ,  Jeannette Whitcomb ,  Wei Huang

IPC分类号： C12Q1/70 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/569 ,  C07K14/16 ,  C07K16/08 ,  C07K14/005 ,  C07K16/10

CPC分类号： G01N33/56988 ,  C07K14/005 ,  C07K14/16 ,  C07K14/162 ,  C07K16/08 ,  C07K16/10 ,  C12Q1/6897 ,  C12Q1/703 ,  G01N33/5044 ,  G01N33/5091 ,  G01N33/56983 ,  G01N2333/16

摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.

摘要翻译： 本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。